{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 44,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes specific clinical trial design details (dosing regimens, patient counts, endpoints).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/13",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.017,
        "w": 0.376,
        "x": 0.113,
        "y": 0.942
      },
      "kind": "disclaimer",
      "text": "UPS = Undifferentiated Pleomorphic Sarcoma; LMS = Leiomyosarcoma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdc0c330-5087-49c2-8830-d126dbb469c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.083,
        "w": 0.88,
        "x": 0.028,
        "y": 0.768
      },
      "kind": "list",
      "text": "Currently studying 3Q4W dosing regimen in LMS / UPS Phase 2, part 1 cohorts (combined n = ~10 - 15); First 6 patients cleared DLT period using the more frequent dosing (3Q4W) – completed Q1’23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3efa96a2-c5d5-409d-b57c-aa17894743f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.533,
        "w": 0.944,
        "x": 0.028,
        "y": 0.256
      },
      "kind": "list",
      "text": "Initiated UPS Phase 2, part 2 potentially registrational study; Enrolling total of ~80 AXL-expressing UPS patients; Primary efficacy endpoint is ORR per RECIST v1.1; Prior systemic regimens limited to ≤3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54df168e-df8d-471a-8dba-c96bc36f4b96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.218,
        "x": 0.033,
        "y": 0.083
      },
      "kind": "title",
      "text": "Sarcoma update",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7de2dd3-d3aa-4461-b56c-a62249f7b4ec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "e244782d-5a81-420e-819d-b97c530d994b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "slides 10-16 provide market sizing information",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 21,
      "from": 11,
      "beatId": "9dc7924a-cf61-4c29-9fd6-e666a2b3daec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "slides 11-21 provide traction information",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e3b4bfda-4f05-4903-9455-c38c0aa043e5",
      "evidence": "slides 11-21 provide data on the effectiveness of CABs",
      "position": 0,
      "objective": "To highlight the potential benefits of CABs in cancer therapy",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}